Eyeluminaries

In this episode John A. Hovanesian, MD, FACS, and Jim Mazzo are live from SightLine at the ASCRS meeting with guests Nicole R. Fram, MD, Kerry D. Solomon, MD, Vance Thompson, MD, and Steve Speares. Welcome to the Eyeluminaries podcast 00:02 Review of episode 32 00:55 Intro of Nicole Fram, MD 01:16 Tell us why the MAHRVELS team is likely to be the leading fundraisers and why you picked your character for the team to portray (The Scarlet Witch)? 02:24 Meeting about complications from cataract surgery, what do you think is the next big phase on how we're going to handle complications with technology? 04:05 Psychology of managing patients/conveying care 05:42 What advice do you give to people who are starting their career? 06:50 Intro of Kerry Solomon, MD 09:30 What do we often get wrong with cataract surgery and what do we often get right? 10:25 How do you stay an entrepreneur and a leading physician? 11:55 What is Operation Sight? How did you create it? 14:19 Where will keratorefractive surgery and lens-based surgery be in 5 or 10 years? 18:30 Intro of Vance Thompson, MD 21:24 What's it like to be ASCRS president? 21:59 What is BRiCS and why is it important? 23:54 You've created a culture; can you talk about that culture you've created at your institute? 29:30 Tell us about your winery! 33:28 Intro of Steve Speares 36:45 ASCRS just wrapped up. Your idea of creating a SightLine with a business approach, what did you do and what was the idea? 38:00 As you look back and you look ahead, what changes do you hope to make? What do you hope your legacy will be at ACSRS? 40:57 Can you expand more on how Washington, DC and Trump administration will impact your society/group? 44:19 Richard Lindstrom in ASCRS hall of fame, tell us your own perspective and a good story 46:29 Preview of episode 34 52:09 Give us your feedback 52:40 Thanks for listening 52:56 Nicole Fram, MD, is an adjunct assistant professor at the John A. Moran Eye Institute at the University of Utah. She is also the secretary for ASCRS, is a member of the Cataract Clinical Committee, and leads the Ophthalmology Quicksand Chronicles podcast with co-host Elizabeth Yeu, MD. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Kerry Solomon, MD, is internationally renowned for LASIK and refractive cataract surgery. He is the co-founder of Operation Sight. He is the former chairman of the ASCRS FDA Committee. Steve Speares, MD, is the executive director at ASCRS. Vance Thompson, MD, is the founder of Vance Thompson Vision and director of refractive surgery in Sioux Falls, SD. He serves as a professor of ophthalmology at the Sanford School of Medicine at the University of South Dakota. Thompson is the immediate past president of ASCRS. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Fram, Speares, Solomon, and Thompson at the time of publication.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news from Washington with guest Mark Leahey. Welcome to the Eyeluminaries podcast :02 Review of episode 31 :40 BVI Medical names a new CCO 2:20 GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions 5:42 Tenpoint submits new drug application for presbyopia combination therapy 7:33 Alcon acquires majority stake in Aurion Biotech 10:29 FDA approves Encelto for macular telangiectasia type 2 14:50 Intro of Mark Leahey 17:28 There is a lot of attention on the HHS restructuring. What are your insights into what has happened to date, and what could happen in the future? 20:10 What do you think about the leadership? 23:44 Let's talk about sustainability. Tell us about the medical device industry's collective interest and challenges in regard to moving toward environmentally sustainable initiatives. 24:59 Let's talk about leadership: Dr. Marty Makary and Dr. Oz. 27:53 Tariffs are an evolving subject. What is the impact on the medical community? What is your impression on how these will affect us in the short term and long term? 33:20 Preview of episode 33 39:27 Give us your feedback 40:23 Team Mah-rvel: the Party for a Purpose 40:41 Thanks 40:58 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Mark Leahey is the president and CEO for the Medical Device Manufacturers Association (MDMA). Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Leahey.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo are live from the Hawaiian Eye meeting with guests Paul Singh, MD, Candy Simerson, Jeffrey Goldberg, MD, PhD, and Roger Goldberg, MD, MBA. Welcome to the Eyeluminaries podcast :02 Review of episode 30 3:23 Intro of Paul Singh, MD 3:40 What are the future trends in glaucoma you're most excited about? 5:10  What challenges do you see in running your practice that didn't exist in your dad's day? 8:36 You've got a great medical office, a very busy consulting and research practice, you play in a band and you have a young family. What advice would you give others in keeping it all in balance? 12:09 Besides your dad and the two of us, who do you look up to in eye care? 14:45 Singh sings a Funkadesi song 18:16 Intro of Candy Simerson 20:36 When you come into a new practice to consult, what are the most common areas you see where improvement can be made? 21:41 What about the finances? What areas in finances do you see where improvement can be made? 24:27 In your many years in ophthalmology, what are the biggest challenges you've experienced? 26:10 What type of practice should consider a sale to private equity? What type of practice should not? 29:34 What advice would you give a company representative who wants to win business from a big ophthalmology practice? 32:29 Intro of the Goldbergs 36:25 Jeff Goldberg, MD, PhD 36:50 Roger Goldberg, MD, MBA 37:21 Jeff, why glaucoma instead of retina? 38:43 Roger, why retina instead of glaucoma? 39:37 Mazzo discusses neuroprotection in retina and glaucoma. 41:14 What is entrepreneurship like today? What's your advice? What is challenging and what is positive? 43:10 Mazzo discusses being realistic about innovations. 48:30 What is private practice like today? 49:31 How do cornea specialists better understand glaucoma specialists? 53:05 How do cornea specialists better understand retina specialists? 54:13 Tell us about emmecell. 55:50 Preview of episode 32 59:19 Give us your feedback 1:00:18 Thanks 1:00:30 Jeffrey Goldberg, MD, PhD, is professor and chair of ophthalmology at the Byers Eye Institute at Stanford University and a member of the National Academy of Medicine. Roger Goldberg, MD, MBA, board certified by the American Board of Ophthalmology and is an active member of the American Society of Retinal Specialists, the Retina Society and the American Academy of Ophthalmology. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Candy Simerson is the senior vice president of practice operations at Vision Integrated Partners. I. Paul Singh, MD, is the president of The Eye Centers of Racine & Kenosha, Ltd., founded in 1981 by his father, Dr. Kanwar A. Singh. He is a founding member of the band, Funkadesi, a mix of Indo-Afro-Caribbean style music. The band tours the world spreading the message “one family, many children.” We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for the Goldbergs, Simerson and Singh at the time of publication.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news and trends and chat with Steven Dell, MD, about his career and the creation of markets in the field of ophthalmology. Welcome to the Eyeluminaries podcast :02 Review of episode 29 1:28  Bausch + Lomb acquires Elios Vision 2:07  ImprimisRx awarded $34.9 million in trademark infringement suit against OSRX 5:00  Study of atropine-based myopia treatment fails to meet primary efficacy endpoint 7:31  Intro of Steven Dell, MD 11:20 You have created markets with new technologies and companies. Can that continue in today's market? 13:28 Dell discusses presbyopia market development. 14:11 You created a questionnaire that you used in your practice, which has become known as the Dell Questionnaire. What do we need to do better in treating our cataract patients? 16:20 What technologies are going to be the most important in the future? 20:24 What has changed in your office environment, i.e., the role of ODs, admin, staff? 22:00 Dell discusses Lindstrom's Integrated Eye Care Delivery Model. 23:08 What advice would you give a younger Steven Dell? 27:16 Neurotech Pharmaceuticals announced that chief commercial officer Scott Hunter died on Dec. 3. 33:06 Give us your feedback 34:43 Thanks 34:51 Steven J. Dell, MD, is a board-certified ophthalmologist in Austin and the Medical Director of Dell Laser Consultants. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Dell at the time of publication.

In this episode, Jim Mazzo and John A. Hovanesian, MD, FACS, are live from Eyecelerator with Mend the Gap hosts Susan MacDonald, MD, and Cathleen McCabe, MD, discussing their humanitarian work. Welcome to the Eyeluminaries podcast :02 In this episode :31 Intro of Susan MacDonald, MD, and Cathleen McCabe, MD 1:00 What started you on this journey to do humanitarian work? 2:18 MacDonald discusses the role of parents in defining of happiness. 7:47 Hovanesian discusses the background of his humanitarian work in Armenia. 8:24 What about the funding of these humanitarian projects? 9:38 What are your stories from doing humanitarian work? 10:59 What advice to do you have for physicians who want to get involved in humanitarian work? 15:43 Hovanesian discusses the commonalities in MacDonald and McCabe's humanitarian missions. 19:11 McCabe discusses the commonalities in Hovanesian and MacDonald's humanitarian missions. 19:38 MacDonald discusses how her humanitarian work began. 20:16 Thank you. 23:49 MacDonald talks about the ophthalmic industry and their contribution to humanitarian work. 24:39 McCabe discusses ways physicians can get involved in humanitarian work without having to travel overseas. 25:30 Visit ACE Global, Cybersight or Operation Sight to get involved. 25:38 Mend the Gap podcast 27:37 Preview of episode 30 29:05 Give us your feedback 29:25 Thanks 30:05 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Susan MacDonald, MD, is president of Eye Corps and associate clinical professor at Tufts School of Medicine. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Cathleen McCabe, MD, is chief medical officer of Eye Health America and medical director of The Eye Associates in Sarasota, FL. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. MacDonald and McCabe report no relevant financial disclosures.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news and trends and chat with Tom Mitro about his career and impact in ophthalmology. Welcome to the Eyeluminaries podcast :02 Review of episode 26 :58 FDA grants fast track designation to brepocitinib for noninfectious uveitis 1:42  I. Howard Fine, MD, esteemed ophthalmologist, dies 3:54 First subjects dosed in phase 3 trial of phentolamine ophthalmic solution for presbyopia 5:48 LENZ Therapeutics submits NDA for drops to treat presbyopia 7:57 Intro of Tom Mitro 10:40 Tell us about your journey in ophthalmology 12:38 Tell us about the new dry eye drug from Signal 12. 15:53 How much sensation is on the forehead if the drug is well tolerated? 24:13 What are your thoughts on the current ophthalmology market? 26:01 Tell us a funny story about Jim Mazzo and about John Hovanesian. 28:51 Preview of episode 29 33:25 Give us your feedback 34:34 Thanks 34:50 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Tom Mitro is the president and chief operating officer for Aerie Pharmaceuticals. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Mitro at the time of publication.

In this special throwback episode, John Hovanesian, MD, and Jim Mazzo revisit their discussions with Steven Schwartz, MD, and Sean Ianculev, MD, about innovations, treatments and entrepreneurship in eye care. Welcome to the Eyeluminaries podcast :10 About Steven Schwartz, MD 2:32 The interview 3:16 Discussion of current innovation in cataract surgery including use of AI, imaging and robotics 4:05 Discussion on Schwartz's involvement in Neurotech MacTel cell-based treatment 6:32 Advances and disappointments in retinal disease treatments? 10:32 How do companies come back from disappointing trial results? 11:07 Why do retina discoveries take so long to develop? 14:31 New dry AMD treatments in development? 15:58  Drug delivery technologies and will retina specialists use them? What do you predict we'll be doing differently in medicine 2 years from now and why? 22:00 What's the difference between a retina and cornea specialist? 23:52 Introduction of Sean Ianchulev, MD, MPH 25:38 The interview 26:29 Impact on Google Glass 30:27 What innovations are you proud of and what projects are you excited about? 35:31 What advice do you have for new entrepreneurs? 42:16 How do you balance your work life and your home life? 45:25 Legends in the field of ophthalmology 47:39 Give feedback at eyeluminaries@healio.com 49:36 Thanks for listening 49:57 Sean Ianchulev, MD, MPH, is a Harvard-trained physician-scientist, a professor of ophthalmology and the head of innovation and technology at New York Eye and Ear Infirmary founder and chairman of Iantrek Inc and Eyenovia and serves as a board member for the American Society of Cataract and Refractive Surgery Foundation and AEYE Health. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. Steven Schwartz, MD, is the Ahmanson professor in ophthalmology and the chief of the retina division at the UCLA Jules Stein Eye Institute and the director of the Diabetic Eye Disease and Retinal Vascular Center. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. You can reach Dr. Schwartz via email at schwartzpatients@jsei.ucla.edu. You can find Dr. Ianchulev on LinkedIn.  Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Schwartz is the co-founder of Horizon Surgical; member on the National Eye Institute Audacious Initiative Scientific executive committee and reports receiving grants from Neurotech, Optos/Nikon, the California Institute of Regenerative Medicine; and investigator fees from Neurotech and Optos/Nikon and the California Institute of Regenerative Medicine.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo chat with Cathleen McCabe, MD, about the ASCRS Foundation and role models in ophthalmology; plus, the latest news in eye care. •    Welcome to the Eyeluminaries podcast :05 •    Review of episode 25 :46 •    Bausch + Lomb acquires Trukera Medical 1:32  •    CMS proposes cutting physician payments for fifth straight year 4:09 •    FDA clears Alcon's Unity cataract system, Unity vitreoretinal cataract system 7:40 •    FDA approves Eylea biosimilar FYB203/Ahzantive 11:07 •    Intro of Cathleen McCabe, MD 13:07 •    American Society of Cataract and Refractive Surgery (ASCRS) has become an important organization to advocate, educate and organize doctors and their practices. As future president of the organization, what vision do you have for the organization? 15:26 •    In reference to your practice, what challenges are you facing and how do you overcome them? 18:59 •    Besides the two of us, who do you admire in ophthalmology? 23:37 •    Tell us about your work, what you do and how you do it. 27:21 •    Preview of episode 27 33:30 •    Thanks 34:58 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Cathleen McCabe, MD, is chief medical officer of Eye Health America and medical director of The Eye Associates in Sarasota, FL. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. McCabe reports no relevant financial disclosures.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo are live from the Octane OTF with Euan Thomson, PhD, Barry Kuppermann, MD, Jeffry Weinhuff, Ehsan Sadri, MD, FACS, and a special announcement from Rich Small. Welcome to the Eyeluminaries podcast :05 Review of episode 24 1:38 Intro of Euan Thomson, PhD 2:10 What kind of companies did you like working for the most? 3:14 Can you comment on why adoption of digital solutions is slow and what we can do about it? 4:15 Geographically speaking, what is the area that is doing the best to incorporate new practices in medicine? 6:04  Can you talk about any real-world evidence of the value of using digital ophthalmic workflows being realized today? 7:51 Intro of Barry Kuppermann, MD, PhD 13:06 Before his passing, you had several years where you worked with one of the most beloved people in ophthalmology, Roger Steinert. What it was like to work with him? Tell us a fun or inspiring story. 15:51 What are the biggest challenges today in resident/fellow education? What advice would you give graduating residents/fellows? 18:05 GHEI has a strong research program. Does it get tougher each year to fund quality research? 20:01 Where do you want to see GHEI in the long-term? 23:55 Intro of Jeffry Weinhuff 26:02 Tell us about your career before entering eye care investing. What is different about our unique specialty within healthcare? 26:38 Tell us about the Visionary Ventures Fund. Is it looking for new physician investors? 30:24 Announcement from Rich Small 34:12 What does Neurotech do? 36:56 Intro of Ehsan Sadri, MD, FACS, FAAO 38:48 Doctors frequently get asked to make investments in start-up companies. How do you decide if an investment is a good one? 42:13 What do you think have been the most innovative companies in eye care during your career? 45:09 Preview of episode 26 49:33 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Barry Kuppermann, MD, PhD, is the Roger F. Steinert professor, chair of the department of ophthalmology and director of the Gavin Herbert Eye Institute at the University of California, Irvine. He also holds a joint appointment with the department of biomedical engineering at UC Irvine. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Ehsan Sadri, MD, FACS, FAAO, is board-certified, fellowship-trained in treating LASIK, cataract and glaucoma surgeries with locations to serve patients in Newport Beach, Santa Ana and Orange. He is also CEO and founder of Visionary Eye Institute and general partner and co-founder of Visionary Ventures Fund (Visionaryvc.com). Rich Small is CEO and member of the board of directors for Neurotech. Euan Thomson, PhD, is the president of ophthalmic devices and head of digital business unit at Carl Zeiss Meditec Inc. Jeffry Weinhuff is the chief investment officer and managing partner of Visionary Ventures Fund, a later-stage venture fund focused on investing in drugs and devices for the eye. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Sadri is the CEO and founder of Visionary Eye Institute and general partner and co-founder of Visionary Ventures Fund. Weinhff is the managing partner of Visionary Ventures Fund. Small is chief executive officer and member of the board of directors for Neurotech. Thomson is the president of ophthalmic devices and head of digital business unit at Carl Zeiss Meditec Inc. Weinhuff is the managing partner of Visionary Ventures Fund.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss leadership in eye care with guest Jack T. Holladay, MD, MSEE, FACS. Brought to you by Johns Hopkins University. •  Welcome to the Eyeluminaries podcast :21 •  Review of episode 23 1:19 •  Blog by John A. Hovanesian, MD, FACS 3:10 •  Merck to acquire EyeBio 4:14 •  FDA approves aflibercept biosimilars Yesafili, Opuviz 6:26 •  Aurion Biotech completes enrollment in phase 1/2 corneal edema cell therapy trial 8:43 •  Intro of Jack Holladay, MD, MSEE 11:10 •  How did you develop a passion for optics? Did you know it was going to be your future? 13:50 •  Holladay's life-threatening situation 16:21 •  Holladay's experience teaching residents 23:50 •  Holladay's optics strategy for improving his golf game 28:33 •  Preview of episode 25 32:25 •  Feedback, questions and guest suggestions at eyeluminaries@healio.com 32:45 Jack T. Holladay, MD, MSEE, FACS, is a clinical professor of ophthalmology at Baylor College of Medicine and retired from clinical ophthalmic practice. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo chat with Terry Kim, MD, and Stephen Lane about their careers and transitions at Alcon. Brought to you by Johns Hopkins University. Welcome to the Eyeluminaries podcast :21 Review of episode 22 1:27 Intro of Stephen Lane 2:41 Intro of Terry Kim, MD 6:02 Lane: Why retire? What's next? 7:54 Kim: Why the move to the industry? 10:35 Lane: What does a chief medical officer do? What did you learn from the time you went from practice to CMO, and what were some of the surprises? 13:14 Kim: What do you see as some of the challenges you will be facing? 18:19 Lane: What will you miss the most about being a CMO? 21:03 In your experience, how do you navigate transitions in a company and lead without losing focus? 24:22 Preview of episode 24 30:45 Feedback, questions and guest suggestions at eyeluminaries@healio.com 31:34 Thanks for listening 32:08   John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Terry Kim, MD, is a professor of ophthalmology at Duke University Eye Center. Stephen Lane is a founding partner of Associated Eye Care. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news in eye care and chat with Wiley A. Chambers, MD, about his career in the FDA and his plans for retirement. Brought to you by Johns Hopkins University Welcome to the Eyeluminaries podcast :21 Review of episode 21 :50 Clobetasol propionate ophthalmic suspension 0.05% approved for postop inflammation, pain 2:49 PulseSight Therapeutics launches with focus on non-viral gene therapies 5:31 FDA clears first investigational new drug application for neuropathic corneal pain 7:59 APX3330 ‘promising' oral treatment option for slowing progression of diabetic retinopathy 10:20 H. Dunbar Hoskins Jr., decorated glaucoma specialist, dies 11:55 Intro of Wiley A. Chambers, MD 13:36 What are you most proud of accomplishing in your 36 years at the FDA? 15:54 What about oral therapies for the eye? 17:30 What do you wish you could change? 18:46 What advice would you give an innovator with a new drug idea? 21:31 What's next for Wiley Chambers? Ocular Advisors, LLC 23:17 What has changed since you left the FDA? 25:11 Second annual drug name awards: The Year of Vs and Ys 27:04 “Needs to buy a vowel” award 28:49 “i before e” award 30:23 “Most likely to be misspelled” award 31:44 “Is there a way to pay for it?” award 33:17 The cutesy award 34:29 “Need an award” award 36:10 Preview of episode 23 38:17 Feedback, questions and guest suggestions at eyeluminaries@healio.com 39:59 Thanks for listening 39:36 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Wiley A. Chambers, MD, is a clinical professor of ophthalmology and adjunct assistant professor of computer medicine at The George Washington University and owner of Ocular Advisors, LLC. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Chambers is the owner of Ocular Advisors, LLC. Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.

Quick episode summary John A. Hovanesian, MD, FACS, and Jim Mazzo sit down with guests Eric D. Donnenfeld, MD, Calvin C. Roberts, MD, Mark L. Baum and Jeannette Bankes to discuss private equity, industry breakthroughs and more. Welcome to the Eyeluminaries podcast :00 Review of episode 20 1:16 Intro of Eric D. Donnenfeld, MD 2:06 Understanding the role of private equity: where does it stand and where is it going? 4:22 Do you see a relief in interest rates and the pace picking up for private equity in the years ahead? 7:19 What are the technologies that you are most excited about? 8:17 What are the things to watch out for? 11:08 Do you have an interesting James Worthy story? 13:34 Intro of Calvin C. Roberts, MD 15:21 Transplanting eyes and Advanced Research Project Agency for Health (ARPA-H) 15:48 How does a chief medical officer work within a company? 18:56 How is what ARPA-H doing different than simply transplanting an eye? 20:42 Intro of Mark L. Baum 26:06 What does the rebranding of the company mean? 27:00 Pharmaceutical names: VEVYE 28:22 How will you market VEVYE in the US? 29:48 Fortisite 31:59 What is the future of the company? 32:47 What do you think of Dr. Wiley Chambers' retirement? 34:09 Intro of Jeannette Bankes 36:51 Describe your last five years in the ophthalmic space: the good, the bad, the ugly 39:16 ·       If you could change anything in the ophthalmic industry, what would it be? 42:53 ·       How excited are you about robotics? 44:06 ·       Tell us about your promotion 44:52 ·       How can we develop a more diverse leadership in ophthalmology? 45:31 Preview of episode 22 48:01 Feedback, questions and guest suggestions at eyeluminaries@healio.com 48:18   Jeannette Bankes is the president and general manager of global surgical franchises for Alcon. Mark L. Baum is the founder, chairman of the board and chief executive officer of Harrow. Eric D. Donnenfeld, MD, is a cornea, laser cataract and refractive surgeon for OCLI Vision. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Calvin C. Roberts, MD, is a program manager for health science futures at ARPA-H. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Bankes is the president and general manager of global surgical franchises for Alcon. Baum is the founder, chairman of the board and chief executive officer of Harrow. Donnenfeld reports consulting widely across the ophthalmic industry with relevant disclosures in this episode as a consultant with Alcon, Bausch + Lomb, LensGen, Ocular Therapeutix and Omeros. Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Thompson is the director of refractive surgery at Vance Thompson Vision. Roberts is program manager for health science futures at ARPA-H.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Vance Thompson, MD, Adrienne Graves, PhD, Sean Ianchulev, MD, and Kristen Harmon Igenito, live from AAO Eyecelerator. Welcome to the Eyeluminaries podcast :01 Review of episode 19 1:31 Intro of Vance Thompson, MD 2:13 What is the secret to your success? 3:54 How many fellows have you trained? 5:20 How has having a fellowship training program at Vance Thompson Vision impacted your practice? 6:23 What are the two recently approved products that you are amazed by? 10:02 What is your favorite wine? 12:55 What is your favorite dad joke? 15:25 Intro of Adrienne Graves, PhD 16:59 How does your background help you serve in the companies and non-profits you work with? 19:43 What do strategics do for companies? 24:13 Prescription drug names 25:53 Intro of Sean Ianchulev, MD, MPH 29:45 How do your ideas evolve? 31:53 ·       Who or what inspires you? 45:58 Intro of Kristen Harmon Ingenito 49:39 How is the software different? 51:45 How is market research changing? 55:19 What are you most optimistic about in terms of trends? The most challenging? 57:18 At what point in your life did you decide to work in market research? 59:05 Preview of episode 21 1:02:32 Feedback, questions and guest suggestions at eyeluminaries@healio.com 1:02:40   Adrienne Graves, PhD, serves as an independent director on the boards of Iveric Bio, Nicox S.A., Greenbrook TMS NeuroHealth, Surface Ophthalmics, Qlaris Bio, and TherOptix and serves as director on the Foundation Boards of the American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology Foundation (Emeritus), Retina Global, Himalayan Cataract Project, and the Foundation Fighting Blindness Retinal Degeneration Fund. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Sean Ianchulev, MD, MPH, is a Harvard-trained physician-scientist, a professor of ophthalmology and the head of innovation and technology at New York Eye and Ear Infirmary founder and chairman of Iantrek Inc and Eyenovia and serves as a board member for the American Society of Cataract and Refractive Surgery Foundation and AEYE Health. Kristen Harmon Ingenito has more than a decade of experience in the ophthalmic industry, with nine of those years analyzing data and reporting for Market Scope. Kristen's industry experience began in 2005 at Market Scope, where she served in many roles, including editing, analysis, sales, and marketing. She then joined an ophthalmic patient education software company, where she worked closely with physicians to help drive value in all aspects of their practices, while also training incoming executives on the business of eye care. She returned to Market Scope with added experience to help expand the company's portfolio of products and services. Source: Market Scope Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Vance Thompson, MD, is a board-certified ophthalmologist who specializes in refractive surgery including laser vision correction, implant vision correction and advanced cataract surgery and is the director of refractive surgery at Vance Thompson Vision. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Graves serves as an independent director on the boards of Iveric Bio, Nicox S.A., Greenbrook TMS NeuroHealth, Surface Ophthalmics, Qlaris Bio, and TherOptix and serves as director on the Foundation Boards of the American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology Foundation (Emeritus), Retina Global, Himalayan Cataract Project, and the Foundation Fighting Blindness Retinal Degeneration Fund. Hovanesian consults widely in the ophthalmic field. Ianchulev is the head of innovation and technology at New York Eye and Ear Infirmary founder and chairman of Iantrek Inc and Eyenovia and serves as a board member for the American Society of Cataract and Refractive Surgery Foundation and AEYE Health. Ingenito develops products and provides services to Market Scope. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Thompson is the director of refractive surgery at Vance Thompson Vision.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Peter Slack, Greg Kunst, Rich Small and Uday Devgan, MD, FACS, FRCS, live from OSN New York. Welcome to the Eyeluminaries podcast :01 Review of episode 18 :18 Intro of Peter Slack 1:47 How did OSN start? 2:35 When did you get into meetings and where do you see meetings going? 5:40 Where do you see media going? 7:46 How did you end up running the Hawaiian Eye Meeting? 10:53 Intro of Greg Kunst 13:59s What will be the biggest challenges introducing a new paradigm for a traditionally surgical disease? 14:52 What can you tell us about Aurion's plans for cell therapy in other front and back of the eye disease, in addition to endothelial cell disease? 17:04 What should I be telling my patients who have future need for endothelial keratoplasty? 19:17 What is the status of Aurion in Japan? Is the competition on the horizon? 22:13 Intro of Rich Small 25:53 Why are you excited about the Encapsulated Cell Therapy Platform? 27:12 Why MacTel? 31:52 What is the status of the Neurotech BLA? 32:26 ·       Give us a good Jim Mazzo story 34:38 Intro of Uday Devgan, MD, FACS, FRCS(Glasg) 37:05 Tell us about how you got started producing one video per day 38:10 Tell us a story about a doctor from far away who is influenced by your teaching 40:38 If you could change one thing in residency training today, what would it be? 41:59 Preview of episode 20 43:51 Feedback, questions and guest suggestions at eyeluminaries@healio.com 44:04   Uday Devgan, MD, FACS, FRCS(Glasg), is Healio|OSN section editor for Ocular Surgery News. He is in private practice, specializing in cataract and refractive surgery, at Devgan Eye Surgery in Los Angeles and a full partner at Specialty Surgical Center in Beverly Hills, California. He has previously served as full clinical Professor of Ophthalmology at the Jules Stein Eye Institute at the UCLA School of Medicine as well as Chief of Ophthalmology at Olive View-UCLA Medical Center and has been actively involved in resident surgical teaching for over two decades. He owns and operates CataractCoach.com. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Greg Kunst is president, chief executive officer and board member at Aurion Biotech. He is focused in areas such as R&D, clinical development, corporate development, strategy, marketing, commercial, business development, market access and medical affairs with extensive knowledge of global health care markets (North America, Latin America, Europe, Asia), global commercialization and market development, upstream and downstream marketing, market access, and medical affairs for medical device, drug delivery systems, diagnostic systems, biotechnology, cell therapies, gene therapies, biologics, and pharmaceutical products. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Peter N. Slack is president and chief executive officer of The Wyanoke Group. Peter is past-Chairman and a current member of the Board of Trustees for the Center for Family Services, a nonprofit human services agency. Other professional titles and memberships have included Board of Directors of the International Association of Association Management Companies and Board of Directors of the American Medical Publishers Association. In addition, Peter is President of the Broadway Theatre of Pitman in Pitman, NJ.  Disclosure: The Wyanoke Group is the holding company for Healio, the producer of the Eyeluminaries podcast. Rich Small is chief executive officer and member of the board of directors for Neurotech. He originally joined Neurotech in July 2007 as the company's chief financial officer. He has in excess of 30 years of both private and public life sciences experience and more than 40 years of overall financial and operational management. Previously Rich served as Senior Vice President and Chief Financial Officer of Point Therapeutics, a publicly traded biotechnology company focused in developing treatments for various cancers. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Devgan owns and operates CataractCoach.com. Hovanesian consults widely in the ophthalmic field. Kunst is president, chief executive officer and board member at Aurion Biotech. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Slack is president and chief executive officer of The Wyanoke Group. Small is chief executive officer and member of the board of directors for Neurotech. The Wyanoke Group is the holding company for Healio, the producer of the Eyeluminaries podcast.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Julia Haller, MD, about the latest developments in retina, residency training and more. Welcome to the Eyeluminaries podcast :01 Review of episode 17, live from Octane OTF :41 Bausch + Lomb makes a number of big moves under the new Brent Saunders regime 1:40 Mark Baum and Harrow Health have also been making a number of acquisitions 3:59 FDA approves Xdemvy for Demodex blepharitis treatment 5:45 Former CEO of Johnson & Johnson Alex Gorsky elected lead director of Neurotech's board 7:47 John begins new clinical committee for ASCRS, digital 9:32 Julia Haller, MD introduction 11:30 ReST Committee update on intraocular inflammation reported in patients who received Syfovre at the American Society of Retina Specialists annual meeting 13:44 The FDA approved Izervay for the treatment of geographic atrophy secondary to age-related macular degeneration, according to a press release from Astellas Pharma 14:16 Novartis is discontinuing the development of GT005 for the treatment of geographic atrophy secondary to dry age-related macular degeneration 14:36 How has the latest retina news affected patients and physicians? 14:53 The development of biosimilars 19:50 Discussion on pricing of products 21:57 The evolution and future of residency programs 23:34 Fun with retina drug names 27:15 Preview of episode 19 at OSN New York 29:46 Feedback, questions and guest suggestions at eyeluminaries@healio.com 30:15 Thanks for listening 30:27 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Julia Haller, MD, is Ophthalmologist-in-Chief and William Tasman, MD Endowed Chair at Wills Eye Hospital and Professor and Chair of Ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University in Philadelphia, PA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Haller reports being on the board of directors at Bristol Myers Squibb, Opthea and Outlook Therapeutics. She is consultant to Aura Biosciences, Bionic Sight, Lowy Medical Research Institute and Regeneron.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, are live at OCTANe OTS with Mark Leahey, Brent Saunders, Yari Mitchell and Robert Dempsey, discussing their experiences and influence across the ophthalmic space. ·       Welcome to the Eyeluminaries podcast :01 ·       Review of episode 16 with Stephen McLeod, MD :28 ·       Preview of episode 17, live at Octane OTS 1:00 ·       Introduce Mark Leahey, president & CEO for the Medical Device Manufacturers Association 1:23 ·       Challenges in medical device 2:19 ·       Is it possible for the government to reduce regulation of medical devices while still protecting patients? 4:32 ·       What is MDMA doing for sustainability? 6:50 ·       What is one issue that device manufacturers need to implement? 9:04 ·       Introduce Brent Saunders, Chairman and CEO of Bausch + Lomb 12:23 ·       What's different about Bausch + Lomb today that wasn't around when you first worked for the company? 13:27 ·       Tell us about other products at Bausch + Lomb. 19:22 ·       Introducing Yari Mitchell, the president of Y Factor Consulting, Inc. 23:31 ·       What have been the most important changes in the ophthalmic industry over the past couple of years? 24:58 ·       What advice would you give to an early-career person? 26:15 ·       Favorite memories of Jim Mazzo 29:14 ·       Introducing Robert Dempsey, CEO and President of AsclepiX Therapeutics 32:10 ·       What was it like to leap from medical sciences to a leadership position? 33:22 ·       Managing a pipeline that includes both retinal and cornea treatments 35:05 ·       How do you establish yourself as a competitor in age-related macular degeneration research in a mature and crowded market with limited resources? 36:10 ·       Creating a retinal treatment delivered via the suprachoroidal route 37:28 ·       The Holland Foundation For Sight Restoration seeking to spread access to eye care for patients and the importance of giving back 38:27 ·       Feedback, questions and guest suggestions at eyeluminaries@healio.com 44:00 ·       Thanks for listening 44:19 Robert Dempsey is the CEO and president of AsclepiX Therapeutics. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Mark Leahey is the president and CEO of the Medical Device Manufacturers Association. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Yari Mitchell is the president of Y Factor Consulting, Inc. Brent Saunders is the chairman and CEO of Bausch + Lomb. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Dempsey is the president and CEO of AsclepiX Therapeutics. Hovanesian consults widely in the ophthalmic field. Leahey is the president & CEO for the Medical Device Manufacturers Association. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Mitchell is the chief business development officer at AcuFocus and the president of Y Factor Consulting, Inc. Saunders is the chairman and CEO of Bausch + Lomb.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Stephen McLeod, MD, about his new position and the future of the American Academy of Ophthalmology. ·       Welcome to the Eyeluminaries podcast :01 ·       Review of episode 15, live from Eyecelerator :37 ·       Preview of episode 17, live at Octane OTF 1:07s ·       Théa to acquire seven branded ophthalmic products from Akorn 2:17 ·       FDA approves Miebo to treat signs, symptoms of dry eye disease 5:11 ·       OCS-01 eye drops meet primary, secondary endpoints in diabetic macular edema phase 3 trial 8:56 ·       ‘One of my greatest honors': Jim Mazzo awarded Ellis Island Medal of Honor 10:38 ·       Introduction Stephen McLeod, MD 12:14 ·       What's been your biggest challenge transitioning from clinical practice to your current position? 14:16 ·       Where is the AAO going now? 17:50 ·       Prior authorizations are the bane of operational existence. What is AAOs role in reforming this system? 22:59 ·       The future of meetings 30:27 ·       Preview of episode 17 35:44 ·       Feedback, questions and guest suggestions at eyeluminaries@healio.com 36:47 ·       Thanks for listening 54:02 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Stephen McLeod, MD, is the CEO of the American Academy of Ophthalmology. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. McLeod is the CEO of the American Academy of Ophthalmology.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, are live at the Eyecelerator 2023 with five special guests to discuss the future and developments in eye care. ·       Welcome to the Eyeluminaries podcast :00 ·       Preview of episode 15 :32 ·       Review of episode 14, STAAR Surgical :40 ·       Nick Curtis, CEO of Lensar 1:41 ·       Lensar is a unique company with loyal customers. How have you achieved that? 3:21 ·       What are the positives and challenges to not having a large organization as support? 4:09 ·       Where do you see the company and its products evolving over the next 5 years? 8:01 ·       Do you think the company is going to grow because you are taking share? Or because you are taking share and the market is going to grow? 10:06 ·       What is the accelerator for market growth? 10:19 ·       Who's your favorite Chicago team? 12:03 ·       Juliet Bakker, managing director and founder of Longitude Capital 13:11 ·       What makes ophthalmology an appealing specialty to you from an investment and a personal perspective? 14:30 ·       Give a sense of how you see Eyecelerator as an investor. 18:32 ·       What did you learn from failed investments? 21:39 ·       What are the signs of success that you look for? 23:03 ·       Ramin Valian, vice president Eye Care Allergan/AbbVie 24:31 ·       What is happening in ophthalmology at AbbVie? 25:21 ·       What were the key learnings after launching Vuity? 27:52 ·       Does ophthalmology have the same momentum as aesthetics? 30:12 ·       Susan Siw Daniels, PhD, chief scientific officer at Avellino Labs 34:11 ·       Why is your background perfect for Avellino? 35:06 ·       What things did you see transform in other specialties that you see potentially happening in ophthalmology? 38:02 ·       What data are you looking for to expand predictive testing and treatments in eye care in the future? 39:07 ·       How do you get ophthalmologists more involved in genetic testing? 40:30 ·       Julie Schallhorn, MD, MS 43:00 ·       What's new at the Eyecelerator? 44:42 ·       What are the signs of success in a startup company? 47:44 ·       What is your advice for people who want to balance their time with a medical career and personal life? 49:45 ·       Preview of episode 16 53:28 ·       Feedback, questions and guest suggestions at eyeluminaries@healio.com 53:56 ·       Thanks for listening 54:02 Juliet Bakker is a managing director and founder of Longitude Capital. Nick Curtis is chief executive officer and member of the board of directors at Lensar. Susan Siw Daniels, PhD, is the chief scientific officer at Avellino. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Julie Schallhorn, MD, MS, is an assistant professor of ophthalmology at UCSF. Ramin Valian is the vice president of Eye Care Allergan/AbbVie. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Bakker serves on the boards of Ceribell, Engogenex, Nalu Medical and RxSight. Curtis is a member of the board of directors for Lensar. Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Schallhorn sits on the Ophthalmic Technology Assessment Committee for Refractive Surgery for the American Academy of Ophthalmolgy and the Young Eye Surgeons Committee for the American Society of Cataract and Refractive Surgeons.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the new leadership at STAAR Surgical with Tom Frinzi, president and CEO; Warren Foust, COO; and Magda Michna, PhD. •    Welcome to the Eyeluminaries podcast :00 •    Review of episode 13 with Gil Kliman, MD :23 •    Review of episode 12, the Annual Drug Name Awards :52 •    Preview of episode 14 1:20 •    Tom Frinzi, president and CEO; Warren Foust, COO; and Magda Michna, PhD, introduction 1:28 •    Tom: What were the qualities and factors that made you choose Foust and Michna to join the STAAR Surgical team? 3:42 •    Magda: Why STAAR Surgical? 6:07 •    Magda: What can you do to help repair the relationship between STAAR Surgical and the FDA? And what do you hope to change at STAAR? 8:07 •    Warren and Magda: What's the 100-day plan? 9:47  •    Tom: How does STAAR Surgical plan to make the ICL exciting for doctors and patients in the US? 13:17 •    Warren: How do you get physicians excited about the ICL? 16:26 •    Tom and Warren: How do you compete with other companies that have an advantage when it comes to selling STAAR's technology? 18:20 •    What kind of impact would you like to have on STAAR Surgical 3 to 5 years from now? 23:14 •    STAAR Surgical and the Jonas Brothers 28:25 •    Wrap up and thank you, Tom, Warren and Magda 29:51 •    Preview of episode 15 30:04 •    Feedback, questions and guest suggestions at eyeluminaries@healio.com 31:00 •    Thanks for listening 31:36 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Warren Foust is the chief operating officer at STAAR Surgical. Thomas Frinzi is the president and chief executive officer at STAAR Surgical. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Magda Michna, PhD, is the chief clinical, regulatory and medical affairs officer at STAAR Surgical. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Foust is the chief operating officer at STAAR Surgical. Frinzi is the president and chief executive officer at STAAR Surgical.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the Silicon Valley Bank collapse and its impact on investing and innovation in the field of ophthalmology with Gilbert H. Kliman, MD. ·       Welcome to the Eyeluminaries podcast :01 ·       Review of episode 12 with Richard L. Lindstrom, MD :30 ·       Preview of episode 13 1:35 ·       Gil Kliman, MD, introduction 2:36 ·       History of Silicon Valley Bank 4:25 ·       Silicon Valley Bank's collapse 6:08 ·       Guest welcome 8:07 ·       Was the collapse a surprise? 8:22 ·       Kliman on major themes of this event being how fast it happened and how unprecedented it was for companies 9:34 ·       How many ophthalmic companies have been affected, and what are the next steps for these companies? 10:16 ·       Kliman on the turning point when the FDIC stepped in on Sunday 11:50 ·       Have you had companies report that they have accessed their funds at Silicon Valley Bank? 12:27 ·       Kliman on his experience with Silicon Valley Bank 12:45 ·       What should companies do going forward, and what are you advising companies? 14:17 ·       Kliman on figuring out a new strategy and the unique issue of 90% of depositors being above the $250,000 FDIC threshold 16:13 ·       What is the survival rate for small banks now? 17:31 ·       What do you think the flavor of the room will be at Eyecelerator@ASCRS? 19:20 ·       Kliman's advice for companies to focus on burn rates 20:35 ·       The physician's perspective for supporting innovation and small business 21:54 ·       How strategics can continue to partner with startups using their venture arm 24:04 ·       Information on the Eyecelerator meeting 25:46 ·       Wrap up and thank you, Gil 26:16 ·       Feedback, questions and guest suggestions at eyeluminaries@healio.com 26:45 ·       Thanks for listening, and preview of episode 14 27:11 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Gil Kliman, MD, is managing partner at InterWest Partners and is co-founder and program director of Eyecelerator. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Kliman is managing partner at InterWest Partners.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Richard L. Lindstrom, MD, about the latest news and trends, as well as his career and his advice for residents and entrepreneurs in the field of ophthalmology.        Welcome to the Eyeluminaries podcast :00        OTF Meeting 01:41        Gezundheit award – Iheezo (chloroprocaine hydrochloride ophthalmic gel) 4:04        Name stolen from a birthday party magician award – Vabysmo (faricimab-svoa) 4:42        The incomplete sentence award – Iyuzeh (latanoprost ophthalmic solution) 5:21        Big improvement on the generic name award – Zimura (avacincaptad pegol) 6:24        Best of the year award – Pegcetacoplan 6:49        Near miss award – Beovu (brolucizumab) 8:08        Awful award – Byooviz (ranibizumab-nuna) 8:45        Guest welcome 9:40        Richard L. Lindstrom, MD, introduction 10:31        FDA grants fast track designation for retinitis pigmentosa treatment 10:36        EyeArt AI system approved in EU for detecting AMD, glaucomatous optic nerve damage 13:14        Amazon launches discount prescription drug service 17:46        Interview with Lindstrom 21:42        What is the biggest innovation in ophthalmology in your career? 22:40        What is coming in the next 10 years? 25:24        What is out there that will get in the way of innovation? 26:54        What advice would you give to residents? 28:35        What advice would you give to entrepreneurs? 30:16        What story can you share about one historical figure in ophthalmology? 31:59        Wrap up and a preview of episode 13, guest David Endicot, Alcon CEO 35:14        Feedback, questions and guest suggestions at eyeluminaries@healio.com 36:29        Thanks for listening 36:53 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. Richard L. Lindstrom, MD, is the founder and an Attending Surgeon at Minnesota Eye Consultants and an Adjunct Professor Emeritus at the University of Minnesota, Department of Ophthalmology. He is a board-certified Ophthalmologist and an internationally recognized leader in corneal, cataract, refractive and laser surgery. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Lindstrom reports consulting with AcuFocus, Alcon, Allergan, Bausch + Lomb, Combangio, CorneaGen, Equinox, Eyevance/Santen, Flying L Partners, Harrow Health, J&J Vision, Lensar, Lentechs, MDbackline, Novartis, Orasis, Schroeder Vision Life Sciences, Sun, Surface, Versant Ventures, Visionary Ventures and Zeiss; holds stocks with Acquea, AcuFocus, Combangio, CorneaGen, Equinox, Flying L Investments, ForSight, Harrow Health, Lensar, Lentechs, MDbackline, Ocular Therapeutix, Orasis, Sight4All, Surface, TearClear, TearLab, TherOptix, Unifeye Vision Partners and Visionary Ventures; board chairman of Surface; sits on the board of Acquea, AcuFocus, Combangio, CorneaGen, Equinox, ForSight, Harrow Health, Lensar, Lentechs, MDbackline, Ocular Therapeutix, Sight4All, TearLab, TherOptix and Unifeye Vision Partners; board observer of TearClear; receives compensation from Ocular Therapeutix; member of the investment committee of Flying L Investments and Visionary Ventures; and a medical advisory board member of Acquea, Foresight, Harrow Health, Ocular Therapeutix, Sight4All, TearClear and TearLab.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest news stories, live from Hawaiian Eye. Welcome to the Eyeluminaries podcast :01 Review of episode 10, the Allergan alumni guests 1:30 Bausch + Lomb announces acquisition of AcuFocus 3:39 Mazzo attributes success to people and the magic of ophthalmology 5:40 Keranova's PhotoEmulsification technique shows promising results 9:25 Centricity CEO discusses latest cataract surgery products 11:04 Orasis submits new drug application for presbyopia drop 12:30 Aldeyra submits NDA for primary vitreoretinal lymphoma treatment 15:27 Iveric Bio submits final part of Zimura new drug application for rolling review 17:30 Tom Frinzi to become CEO of STAAR Surgical 22:37 Wrap up and a preview of episode 12 25:38 Feedback, questions and guest suggestions at eyeluminaries@healio.com 27:39 Thanks for listening 28:00 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, sit down with Gavin Herbert, Tom Burns, Andy Corley and Tom Mitro to discuss their days at Allergan and what they have learned from their experiences. Welcome to the Eyeluminaries podcast :37 News and notes with John and Jim 1:01 Viatris to acquire Oyster Point, Famy Life Sciences 1:06 Ocuphire enters global license agreement with Famy for Nyxol development 4:20 Eyenuk secures $26 million in Series A funding 6:24 Encapsulated cell therapy shows positive results for macular telangiectasia 8:31 Introduction of the Allergan alumni 10:35 The interview 12:10 Gavin Herbert – what is the secret to great leadership? 12:18 Tom Burns – what have you learned from Allergan that has led to your success? 17:48 Andy Corley 20:38 Tom Mitro 24:50 Jim Mazzo 29:41 Herbert – principles 30:29 Corley – producing jobs 32:01 Herbert – alumni 32:50 Wrap up and a preview of episode 10 33:38 Feedback, questions and guest suggestions at eyeluminaries@healio.com 34:06 Thanks for listening 34:14 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. Gavin Herbert is a board member of the Doheny Eye Institute and the Nixon Foundation, as well as a life trustee of the University of Southern California. He was the co-founder and chief executive officer of Allergan Inc. Tom Mitro is the past president and chief operating officer at Aerie Pharmaceuticals. Tom Burns serves as the chief executive officer and the chairman of the board for Glaukos. Andy Corley is the founder of Yelroc Consulting, Inc. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Herbert reports being a board member of the Doheny Eye Institute and the Nixon Foundation, as well as a life trustee of the University of Southern California. He was the co-founder and chief executive officer of Allergan Inc. Mitro is the past president and chief operating officer at Aerie Pharmaceuticals. Burns serves as the chief executive officer and the chairman of the board for Glaukos. Corley is the founder of Yelroc Consulting, Inc.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest ophthalmic industry news and interview Steve Schallhorn, MD, Julie Schallhorn, MD, Craig S. Schallhorn, MD, Erin Schallhorn and Eileen Schallhorn. Welcome to the Eyeluminaries podcast :01 A preview of the guests :32 A review of the previous episode 1:32 News and notes with John and Jim 1:52 Iantrek raises $23 million for MIGS device trials 1:57 Q&A: Data show safety of in-office ophthalmic surgery 4:34 TearLab rebrands as Trukera Medical 7:04 Coherus to launch ranibizumab biosimilar in October 10:46 Introduction of the Schallhorn family 14:38 The interview 16:29 Steve Schallhorn, MD – naval aviator and Top Gun 17:04 Eileen Schallhorn – fostering the children to become the best they can be 20:05 Steve and Eileen – three successful children in the field of ophthalmology 21:28 Julie Schallhorn, MD – growing up and becoming an ophthalmologist 22:57 Craig Schallhorn, MD – specializing in retina 24:52 Erin Schallhorn (Powers) – choosing the industry of ophthalmology 27:36 Steve – never underestimate Erin 31:06 Julie and Craig – following in their father's footsteps 32:02 Julie, Craig and Erin – What do you want to say to mom and dad? 36:32 Eileen – love makes it work 38:32 Wrap up and a preview of episode ten 39:04 Feedback, questions and guest suggestions at eyeluminaries@healio.com 39:38 Thanks for listening 40:32 Steve Schallhorn, MD, is a board certified, licensed ophthalmologist in private practice in San Diego, CA. He is a clinical professor of ophthalmology at the University of California, San Francisco; chief medical officer for Carl Zeiss Meditec and chairman of the Optical Express Medical Advisor Board. Julie Schallhorn, MD, is associate director of the University of California, San Diego, residency program in ophthalmology, organizing classroom and research curricula for residents. Craig Steven Schallhorn, MD, is an ophthalmologist in San Francisco, CA. Erin Schallhorn Powers is the vice president of Global Marketing & Product Strategy at BVI Medical. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. You can find Dr. Ianchulev on LinkedIn: Sean Ianchulev, MD, MPH. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest ophthalmic industry news and interview Sean Ianchulev, MD, MPH. Welcome to the Eyeluminaries podcast :01 A review of the previous episode :23 News and notes with John and Jim 1:31 Alcon to acquire Aerie Pharmaceuticals 1:40 Glaukos, iVeena enter licensing agreement for keratoconus treatment 5:20 Lions Eye Institute to acquire SightLife 8:37 Novaliq submits NDA for CyclASol for treatment of dry eye disease 11:37 AbbVie, iSTAR enter alliance to support MINIject MIGS device 13:30 Introduction of Sean Ianchulev 16:30 The interview 18:37 Impact on Google Glass 21:32 What innovations are you proud of and what projects are you excited about? 26:20 What advice do you have for new entrepreneurs? 33:04 How do you balance your work life and your home life? 36:24 Legends in the field of ophthalmology 38:07 Give feedback at eyeluminaries@healio.com 39:39 A preview of the next episode of Eyeluminaries 39:54 Thanks for listening 40:26 Sean Ianchulev, MD, MPH, is a Harvard-trained physician-scientist, a professor of ophthalmology and the head of innovation and technology at New York Eye and Ear Infirmary founder and chairman of Iantrek Inc and Eyenovia and serves as a board member for the American Society of Cataract and Refractive Surgery Foundation and AEYE Health. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. You can find Dr. Ianchulev on LinkedIn: Sean Ianchulev, MD, MPH. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest ophthalmic industry news and interview David F. Chang, MD. Welcome to the Eyeluminaries podcast :10 A review of the previous episode :30 News and notes with John and Jim 1:15 AMA president outlines 5 actions for policymakers to take to support physicians 1:20 Aetna drops prior authorization requirement for cataract surgery 4:10 Yutiq approved in China 6:21 Lensar received FDA 510(k) clearance for its next-generation Ally adaptive cataract treatment system 8:55 Introduction of David F. Chang, MD 10:30 The interview 11:48 How did EyeSustain develop and how can people become involved? 13:54 What are you doing differently already in your surgery center or office to reduce waste? 18:27 Tell us your thoughts on same-day bilateral cataract surgery and intracameral antibiotics 21:02 What technological advancements do you see coming here from outside the U.S? 25:18 An anecdote on parenting, baseball and myopia 31:16 A preview of the next episode of Eyeluminaries 33:08 David F. Chang, MD, is a world-renowned cataract surgeon and innovator in the field. He is clinical professor of ophthalmology at the University of California, San Francisco, and is in private practice in Los Altos, Calif. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest ophthalmic industry news and interview Allison W. Shuren, JD, MSN. Welcome to the Eyeluminaries podcast :10 A review of the previous episode :30 News and notes with John and Jim 1:20 On the return of in-person medical meetings 1:28 Byooviz, biosimilar to Lucentis, to be available July 1 2:40 First patient dosed in the phase 3 registrational COMET-2 study of AR-15512 for the treatment of dry eye disease signs and symptoms 5:50 Apellis Pharmaceuticals submitted a new drug application to the FDA for intravitreal pegcetacoplan, for the treatment of geographic atrophy secondary to age-related macular degeneration 9:04 Kala enters agreement to sell commercial portfolio to Alcon 11:30 FTC opens investigation into pharmacy benefit managers 13:30 Introduction of Allison W. Shuren, JD, MSN 15:45 The interview 17:44 The FTC investigation of pharmacy benefit managers and other enforcement trends 18:12 Have you seen an increase in cases against practices and industry and if so, why? 19:36 Prior authorization and trends in reduced access to care 22:12 What advice would you give to practices who are considering selling to private equity? 23:50 What advice are you giving to the private equity buyers? 25:32 What advice would you give to young surgeons coming out now to succeed in the future? 27:19 Introducing the next guest, David Chang, MD 30:55 Allison W. Shuren, JD, MSN, is a partner at the law firm Arnold & Porter, where she co-chairs the life sciences and healthcare regulatory practice and advises a wide range of health care clients on regulatory, compliance, enforcement and legislative matters. Before starting her career as a lawyer, she was a practicing critical care pediatric nurse practitioner. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. You can reach Shuren via email at allison.shuren@arnoldporter.com. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest ophthalmic industry news and interview Eve Higginbotham, MD. Welcome to the Eyeluminaries podcast :10 A review of the previous episode :30 News and notes with John and Jim 1:20 The FDA approved STAAR Surgical's EVO/EVO+ Visian implantable Collamer lens for the correction of myopia and myopia with astigmatism 1:28 News on two new drop treatments for presbyopia, Visus' Brimochol PF and Allergan/AbbVie's Vuity 4:56 Ocuphire's Nyxol reduced pharmacologically induced mydriasis 7:12 Axim Biotechnologies rapid test for dry eye inflammatory biomarker 9:20 Representation in medicine fails to reflect diversifying U.S. population 10:50 Introduction of Eve Higginbotham, MD 12:25 The interview 14:52 The gender recession in corporate advancement during the pandemic 15:50 What will change things and get us to a better place in ophthalmology? 17:20 What needs to change in residency training programs? 20:50 What barriers are there to getting sufficient time in the OR? 24:30 Representation on corporate boards 25:15 How do you get new technologies such as presbyopia drops into the training curriculum? 27:05 The latest innovations in glaucoma 30:42 How MIGS has changed practice 32:15 What is the secret to being able to enjoy golfing? 33:00 Eve J. Higginbotham, SM, MD, ML, is the vice dean for Penn Medicine's Office of Inclusion, Diversity and Equity, senior fellow, Leonard David Institute for Health Economics and professor of ophthalmology at the University of Pennsylvania. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. You can reach Dr. Higginbotham via email at ehig@upenn.edu. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.

Steven Schwartz, MD, sits down with hosts, Jim Mazzo and John A. Hovanesian, MD, FACS, to discuss the advances and disappointments in retinal disease treatments, innovations in cataract surgery and more. Welcome to the Eyeluminaries podcast :10 A review of the previous episode :42 News and notes with John and Jim 1:57 Alcon announces fourth-quarter earnings statement 2:03 FDA approves J&J Vision AcuVue Theravision contact lens with ketotifen 6:25 Enhanced monofocal IOLs gaining popularity in Europe 8:47 Ophthalmologists participating in clinical trials 11:30 About Steven Schwartz 12:53 The interview 13:40 Discussion of current innovation in cataract surgery including use of AI, imaging and robotics 14:25 Discussion on Schwartz's involvement in Neurotech MacTel cell-based treatment 15:51 Advances and disappointments in retinal disease treatments? 20:50 How do companies come back from disappointing trial results? 21:28 Why do retina discoveries take so long to develop? 25:00 New dry AMD treatments in development? 26:29 Drug delivery technologies and will retina specialists use them? 29:33 What do you predict we'll be doing differently in medicine 2 years from now and why? 32:31 What's the difference between a retina and cornea specialist? 34:15 Conclusion and preview of next guest, Eve Higginbotham, MD 36:17 Steve, thank you very much 37:37 Look forward to seeing you next time 37:47 Steven Schwartz, MD, is the Ahmanson professor in ophthalmology and the chief of the retina division at the UCLA Jules Stein Eye Institute and the director of the Diabetic Eye Disease and Retinal Vascular Center.  John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. You can reach Dr. Schwartz via email at schwartzpatients@jsei.ucla.edu. Disclosures: Hovanesian consults widely in the ophthalmic field and specifically with Alcon, Ivantis and Sight Sciences, who are discussed in this episode. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Schwartz is the co-founder of Horizon Surgical; member on the National Eye Institute Audacious Initiative Scientific executive committee and reports receiving grants from Neurotech, Optos/Nikon, the California Institute of Regenerative Medicine; and investigator fees from Neurotech and Optos/Nikon and the California Institute of Regenerative Medicine.

In this episode, hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest news in eyecare, then speak with Eric Rosenberg, DO, about the current state and future of digital ophthalmology. Intro :10 Brief recap of episode 2 with Nicole Fram :55 News and Notes 1:31 Generic of Allergan's Restasis by Mylan Pharmaceuticals and discussion of generics in the ophthalmic space 2:05 Aramis Biosciences in phase 2 neuromodulator dry eye program and discussion of dry eye 5:12 Jim discusses Aetna's prior authorization for cataract surgery 6:54 Bilateral same day cataract surgery discussion 8:48 Eric Rosenberg, DO, introduction 10:48 What is digital? What is the meaning of digital? 11:38 Goals of the Digital Ophthalmic Society 17:33 Barriers to adoption of digital 22:34 What will DOS be discussing at Eyecelerator@ASCRS? 23:56 What Rosenberg hopes the DOS will achieve in the future 27:38 Thank you, Eric 29:42 Roger Ohanesian to receive Chang/Crandall Humanitarian Award at ASCRS 30:01 Sneak peek at the next episode 32:18 For more information: John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. Eric Rosenberg, DO, is a cornea, cataract, and refractive surgeon at SightMD. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. You can reach Dr. Rosenberg via email at ericr29@gmail.com. To learn more about the DOS, visit: https://www.digitalophthalmicsociety.com/. Disclosures: Hovanesian consults widely in the ophthalmic field and specifically with Alcon, Ivantis and Sight Sciences. Mazzo reports being an adviser for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Centricity Vision, Crystilex, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Rosenberg at the time of publication.

Nicole Fram, MD, MPH, is a wearer of many hats and seems to be able to wear them all well. In this episode, she sits down with hosts, Jim Mazzo and John A. Hovanesian, MD, FACS, to discuss taking over as managing partner for Advanced Vision Care and Samuel Masket, MD, balancing her many professional roles, and shares her point of view on new and upcoming products and technologies in eye care. Welcome to the Eyeluminaries podcast :10 News and notes with John and Jim 1:07 Alcon completes acquisition of Ivantis 1:11 FDA approves Genentech's Vabysmo for AMD, DME 3:54 Sight Science's TearCare system for MGD receives 510(k) clearance 6:32 About Nicole Fram 9:54 The interview 11:23 What is it like to take over a practice from Sam Masket? 13:02 Being a mom who is running a practice, sitting on boards, being an OSN section editor now, and chairing or sitting on all these committees, how on earth do you do it all, Nicole? 15:51 Are you getting better at saying no to some things? 18:05 I know COVID made us kind of rethink everything, which included meetings. But what do you think the future of these meetings are? 19:32 What do you think about the way this market is going to evolve? How is pilocarpine going to compete with some of these other products? And how do we differentiate between these different offerings? 22:39 How are you deciding which companies' technologies you decide to spend your very valuable time on? 29:25 What do you think about the ICA lens? Is that going to take some of what you used to do with LALs? Where's that going to fit in potentially? 31:53 Thank you, Nicole Fram 36:12 Thanks for listening 36:50 Nicole Fram, MD, is the managing partner of Advanced Vision Care and a clinical instructor of ophthalmology at the Stein Eye Institute, University of California, Los Angeles. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. You can reach Dr. Fram on Twitter @NicoleFramMD. Disclosures: Hovanesian consults widely in the ophthalmic field and specifically with Alcon, Ivantis and Sight Sciences, who are discussed in this episode. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Healio could not confirm relevant financial disclosures for Fram at the time of publication.

In this episode, David W. Parke II, MD, sits down with hosts, Jim Mazzo and John A. Hovanesian, MD, FACS, to discuss stepping down as the American Academy of Ophthalmology CEO, the highlights of what he accomplished during this time, and his thoughts on the future of ophthalmology. Welcome to the Eyeluminaries podcast :10 News and notes with John and Jim 1:30 Allergan's Vuity presbyopia-correcting drop gains FDA approval 1:36 Glaukos' two phase 2 clinical trials for dry eye disease and presbyopia 3:30 Acufocus' receives “approvable” letter on IC-8 IOL 5:42 Harrow Health acquires four ophthalmic drugs from Novartis 8:40 Welcome David Parke 10:54 What's it like having three generations of ophthalmologists in your family? 11:27 Why leave the AAO presidency now? What's the significance of 2022? 13:29 Tell us some of the highlights what are you most proud of during those past years 16:18 What are your thoughts on the consolidation from private equity? 19:55 As you look ahead to the future of ophthalmology, what worries you the most and what excites you the most, David? 25:17 What are your thoughts on the future of meetings? 31:23 Tell our listeners a little bit about what Verana Health does and what you'll be doing there 35:49 Thank you, David Parke! 40:26 Thanks for listening 41:00 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss Meditec and AMO. David W. Parke II, MD, is chairman of the board at Verana Health and former CEO of the American Academy of Ophthalmology. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field and specifically with Acufocus, Allergan, Glaukos and Novartis who were mentioned in this episode. Mazzo reports being an adviser for Anivive Lifesciences, Avellino, Bain Capital, CVC Capital, Zeiss Labs; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Centricity Vision, Crystilex, IanTech, Lensgen,  and Visus. Parke reports a financial interest in Verana Health.   

In each episode, your hosts John A. Hovanesian, MD, and Jim Mazzo explore the latest news and trends with newsmakers and visionaries in eye care.  Hovanesian is OSN Associate Medical Editor and in private practice at Harvard Eye Associates in Laguna Beach, California Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss Meditec and AMO.